Clinical Trials

Multiple Myeloma

NCT07276698 2025-12-11

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

39 enrolled

Phase 1 Active not recruiting

Lymphoma, Extranodal NK-T-Cell

NCT02091245 2025-12-02

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

16 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05985161 2025-11-26

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

45 enrolled

GenitourinarySarcoma

Wilms Tumor, Neurofibrosarcoma, Rhabdoid Tumor

NCT02199665 2025-11-03

SINE

52 enrolled

Multiple Myeloma

NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Phase 1/2 Active not recruiting

165 enrolled

Extensive Stage Lung Small Cell Cancer

NCT03147885 2025-09-29

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

43 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04850755 2025-09-25

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

11 enrolled

Advance Solid Malignancies

NCT06822972 2025-09-02

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

27 enrolled

Multiple Myeloma

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

35 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT07094464 2025-07-30

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

20 enrolled

Leukemia, Myeloid, Acute

NCT05035745 2025-07-25

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2 Recruiting

63 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06114004 2025-06-25

SeliSarc

88 enrolled

Sarcoma

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

34 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT07002099 2025-06-03

Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

26 enrolled

Lymphoma

NCT06449482 2025-05-30

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Phase 1/2 Terminated

6 enrolled

Leukemia, Myeloid, Acute

NCT04811196 2025-05-29

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

56 enrolled

GynecologicSarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Neurofibrosarcoma

NCT06900088 2025-03-28

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

MyeloidOther hematologic neoplasm

20 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04717700 2025-03-18

SABLe

Phase 2 Active not recruiting

50 enrolled

Multiple Myeloma

NCT06853678 2025-03-03

Second-line Immunotherapy for ES-SCLC

Phase NA Recruiting

30 enrolled

Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

25 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

15 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT06765928 2025-01-09

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

73 enrolled

Phase 2 Enrolling by invitation

Leukemia, Myeloid, Acute

NCT06664970 2024-10-30

A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

39 enrolled

MDS

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

LymphoidOther hematologic neoplasm

78 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3 Recruiting

50 enrolled

Phase 2 Active not recruiting

Recurrence, Leukemia, Myeloid, Acute

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

52 enrolled

Phase 3 Not yet recruiting

Multiple Myeloma

NCT06613035 2024-09-25

Twice-per-weekSelinexor, 2 Days Melphalan

126 enrolled

Leukemia, Myeloid, Acute

NCT06573138 2024-08-27

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

18 enrolled

Lymphoma, Extranodal NK-T-Cell

NCT06573151 2024-08-27

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

28 enrolled

Lymphoma

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2 Withdrawn

Multiple Myeloma, Neoplasm, Residual

NCT05422027 2024-06-17

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

42 enrolled

Multiple Myeloma

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05952687 2024-03-27

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Phase 1 Withdrawn

CNS

Central Nervous System Neoplasms, Rhabdoid Tumor

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer